KA
VRTX icon

Kovack Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Kovack Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$655K Sell
1,315
-1,971
-60% -$874K 0.03% 527
2026
Q1 		$1.47M Sell
3,286
-2,905
-47% -$1.35M 0.08% 248
2025
Q4 		$2.81M Buy
6,191
+5,044
+440% +$2.17M 0.13% 137
2025
Q3 		$449K Sell
1,147
-133
-10% -$55.6K 0.04% 360
2025
Q2 		$570K Buy
1,280
+24
+2% +$11.1K 0.06% 296
2025
Q1 		$609K Buy
1,256
+19
+2% +$8.85K 0.06% 256
2024
Q4 		$498K Sell
1,237
-20
-2% -$9.27K 0.05% 302
2024
Q3 		$585K Buy
1,257
+45
+4% +$21.6K 0.06% 275
2024
Q2 		$568K Buy
1,212
+127
+12% +$55.1K 0.06% 278
2024
Q1 		$454K Buy
1,085
+5
+0.5% +$2.11K 0.05% 269
2023
Q4 		$439K Buy
1,080
+41
+4% +$15.1K 0.05% 329
2023
Q3 		$361K Buy
1,039
+76
+8% +$26.6K 0.05% 338
2023
Q2 		$339K Sell
963
-53
-5% -$17.9K 0.04% 389
2023
Q1 		$320K Buy
1,016
+71
+8% +$21.3K 0.04% 396
2022
Q4 		$273K Buy
945
+82
+10% +$25K 0.04% 427
2022
Q3 		$250K Sell
863
-802
-48% -$231K 0.04% 460
2022
Q2 		$469K Sell
1,665
-1,161
-41% -$311K 0.06% 330
2022
Q1 		$737K Buy
2,826
+721
+34% +$171K 0.08% 285
2021
Q4 		$462K Buy
+2,105
New +$409K 0.04% 405
2021
Q1 		– Sell
-1,094
Closed -$259K – 704
2020
Q4 		$259K Sell
1,094
-520
-32% -$119K 0.04% 452
2020
Q3 		$439K Buy
1,614
+136
+9% +$37.5K 0.08% 255
2020
Q2 		$429K Buy
1,478
+69
+5% +$18.7K 0.08% 240
2020
Q1 		$335K Buy
+1,409
New +$323K 0.08% 270
2019
Q3 		– Sell
-1,157
Closed -$212K – 535
2019
Q2 		$212K Sell
1,157
-256
-18% -$44.8K 0.05% 384
2019
Q1 		$260K Sell
1,413
-71
-5% -$13.1K 0.06% 323
2018
Q4 		$246K Buy
1,484
+60
+4% +$10.4K 0.07% 308
2018
Q3 		$274K Buy
+1,424
New +$254K 0.07% 313

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kovack Advisors's VRTX Position: Q2 2026 in Review

Kovack Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 60% in Q2 2026, selling an estimated $874K and leaving 1,315 shares worth $655K. The position accounts for 0.03% of the portfolio, ranked #527.

Kovack Advisors first reported a position in VRTX in Q3 2018 and has held it in 27 quarters since. The position peaked at $2.81M in Q4 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Kovack Advisors held 1,315 shares of Vertex Pharmaceuticals worth $655K as of Q2 2026.
  • Kovack Advisors sold 1,971 Vertex Pharmaceuticals shares in Q2 2026, an estimated $874K.
  • Vertex Pharmaceuticals made up 0.03% of Kovack Advisors's portfolio in Q2 2026, its #527 holding.
  • Kovack Advisors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 27 quarters since.
  • Kovack Advisors's Vertex Pharmaceuticals position peaked at $2.81M in Q4 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kovack Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.